Lansu Jules, Van Houdt Winan J, Schaapveld Michael, Walraven Iris, Van de Sande Michiel A J, Ho Vincent K Y, Haas Rick L
Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
Sarcoma. 2020 Sep 22;2020:2437850. doi: 10.1155/2020/2437850. eCollection 2020.
The purpose of this study was to evaluate the overall survival (OS) and associated characteristics for patients with Myxoid Liposarcoma (MLS) over time in The Netherlands.
A population-based study was performed of patients with primary localized ( = 851) and metastatic ( = 50) MLS diagnosed in The Netherlands between 1989 and 2016, based on data from the National Cancer Registry.
The median age of the MLS patients was 49 years, and approximately two-thirds was located in the lower limb. An association was revealed between age and the risk of having a Round Cell (RC) tumor. OS rates for primary localized MLS were 93%, 83%, 78%, and 66% after 1, 3, 5, and 10 years, respectively. The median OS for patients with metastatic disease at diagnosis was 10 months. Increasing age (Hazard Ratio (HR) 1.05, =0.00), a tumor size >5 cm (HR 2.18; =0.00), and tumor location (trunk HR 1.29; =0.09, upper limb HR 0.83; =0.55, and "other" locations HR 2.73; =0.00, as compared to lower limb) were independent prognostic factors for OS. The percentage of patients treated with radiotherapy (RT) increased over time, and preoperative RT gradually replaced postoperative RT. In contrast to patients with localized disease, significant improvement of OS was observed in patients with metastatic disease over time.
In this large nationwide cohort, tumor size and tumor location were independent prognostic factors for OS. Furthermore, a higher probability of an RC tumor with increasing age was suggested. An increased use of RT over the years did not translate into improved OS for localized MLS.
本研究旨在评估荷兰黏液样脂肪肉瘤（MLS）患者的总生存期（OS）及相关特征随时间的变化情况。
基于荷兰国家癌症登记处的数据，对1989年至2016年间在荷兰诊断出的原发性局限性（n = 851）和转移性（n = 50）MLS患者进行了一项基于人群的研究。
MLS患者的中位年龄为49岁，约三分之二位于下肢。年龄与圆形细胞（RC）肿瘤风险之间存在关联。原发性局限性MLS患者1年、3年、5年和10年后的OS率分别为93%、83%、78%和66%。诊断时患有转移性疾病的患者的中位OS为10个月。年龄增加（风险比（HR）1.05，P = 0.00）、肿瘤大小>5 cm（HR 2.18；P = 0.00）和肿瘤位置（躯干HR 1.29；P = 0.09，上肢HR 0.83；P = 0.55，“其他”位置HR 2.73；P = 0.00，与下肢相比）是OS的独立预后因素。接受放疗（RT）治疗的患者比例随时间增加，术前RT逐渐取代术后RT。与局限性疾病患者不同，转移性疾病患者的OS随时间有显著改善。
在这个全国性的大型队列中，肿瘤大小和肿瘤位置是OS的独立预后因素。此外，提示随着年龄增加出现RC肿瘤的可能性更高。多年来RT使用的增加并未转化为局限性MLS患者OS的改善。
